DDInter1382 DDInter624
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Palonosetron {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Palonosetron {u} (Compound) causes {v} (Side Effect) Glycosuria
Glycosuria {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Lopinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lopinavir
Lopinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Praziquantel {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Efavirenz
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Tapentadol
Tapentadol {u} (Compound) causes {v} (Side Effect) Hallucination
Hallucination {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Ezogabine {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ill-defined disorder {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Palonosetron (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Efavirenz (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Palonosetron (Compound) resembles Praziquantel (Compound) and Praziquantel (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Efavirenz (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Tapentadol and Tapentadol (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Efavirenz (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Efavirenz (Compound)